FDA Seeks Industry Input on How to Monitor AI Medical Devices After Clearance

The FDA’s request for industry feedback on post-clearance safety monitoring marks an important shift in how AI medical devices are regulated. Rather than focusing only on premarket review, the agency appears to be moving toward a lifecycle model in which ongoing performance monitoring becomes part of the regulatory bargain.

That is especially relevant for AI systems, which are not static products. Their behavior can change with software updates, workflow modifications, distribution shifts, and real-world patient populations that differ from the datasets used in development. For regulators, this creates a challenge: the traditional clearance model was built for devices whose performance profile is comparatively stable.

Industry input is likely being sought because no single monitoring framework will fit every use case. An AI tool used in radiology, triage, or procedural planning may need different signals, thresholds, and reporting obligations. The agency’s ask suggests it understands that effective oversight will depend on practical, scalable surveillance mechanisms rather than purely theoretical standards.

For manufacturers, the message is clear: post-market monitoring is moving from optional good practice to expected infrastructure. Companies that can demonstrate real-world tracking, anomaly detection, and rapid response to performance drift may gain an advantage not just with regulators, but with hospital buyers who are increasingly sensitive to AI risk.